Page 6,806«..1020..6,8056,8066,8076,808..6,8206,830..»

AuxoCell Laboratories Licenses Umbilical Cord Tissue Stem Cell Service to Brazil’s CordVida

Posted: Published on June 6th, 2012

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Leading stem cell therapeutic and regenerative medicine company, AuxoCell Laboratories, Inc., today announced an agreement with CordVida, a Brazilian stem cell cryopreservation company, which will allow CordVida to expand its services. Families who select CordVida to store umbilical cord blood will now have the opportunity to bank stem cells from an additional source cord tissue. With this agreement, AuxoCell broadens its international reach to South America. At AuxoCell, we are pleased by the opportunity to provide this groundbreaking technology to families around the globe, said Rouzbeh R. Taghizadeh, PhD, Chief Scientific Officer of AuxoCell Laboratories, Inc. CordVida is Brazils premier cord blood bank and adheres to the highest quality standards. It is for that reason that we have selected them as our exclusive partner in Brazil. Cord tissue has an abundant source of mesenchymal stem cells (MSCs). Currently, there is a significant amount of research underway focused on mesenchymal stem cells extracted from cord tissue. MSCs are rapidly becoming the leading stem cell in regenerative medicine studies, and MSCs from a variety of sources are in use in over 150 clinical trials. The AuxoCell cord tissue technology represents the gold standard in the industry, as its technology … Continue reading

Posted in Mesenchymal Stem Cells | Comments Off on AuxoCell Laboratories Licenses Umbilical Cord Tissue Stem Cell Service to Brazil’s CordVida

Vitamin D and Erectile Dysfunction

Posted: Published on June 6th, 2012

Newswise A paper just published hypothesizes that vitamin D deficiency may be an important risk factor for erectile dysfunction (ED). Evidence cited supporting the link between low vitamin D and ED include that those with Asthma, depression, falls and fractures, multiple sclerosis, and periodontal disease are at greater risk of having ED. In addition, those with ED are at greater risk of developing cardiovascular disease, diabetes mellitus, and metabolic syndrome. All of these diseases are linked to vitamin D deficiency. Vascular problems account for about half the cases of ED. There is a large body of research finding that vitamin D can maintain vascular health. The mechanisms appear to include suppressing the activity of the renin-angiotensin system, thereby lowering blood pressure, improving endothelial function, reducing inflammation, and reducing vascular calcification. Solar ultraviolet (UV) light is the primary source of vitamin D for most people. In addition, UV increases nitric oxide concentrations in the blood, which also appears to reduce the risk of ED. Those diagnosed with ED should consider having serum 25-hydroxyvitamin D [25(OH)D] concentration measured, then adopt a program to increase concentrations to at least 40 ng/ml (100 nmol/l) through vitamin D supplementation and/or increased solar UVB exposure. Serum … Continue reading

Posted in Erectile Dysfunction | Comments Off on Vitamin D and Erectile Dysfunction

Bio-Matrix’ Regen BioPharma Unit Establishes Scientific Advisory Board and Research Relationship With Clinartis in …

Posted: Published on June 6th, 2012

SAN DIEGO, CA--(Marketwire -06/06/12)- Bio-Matrix Scientific Group (BMSN) (BMSN) announced today that its Regen BioPharma unit has appointed three internationally renowned regenerative medicine experts to its Scientific Advisory Board (SAB). The new SAB members appointed are David White, M.D., PhD; Wei-Ping Min, M.D., PhD and Vlad Bogin, M.D. Dr. White is a member of the Surgery and Immunology faculty of The Schulic School of Medicine, University of Western Ontario. He is one of the leading experts on using regenerative medicine transplant procedures to treat pancreatic conditions, including diabetes. He is also the Chief Scientific Officer of Sernova Corp and was formerly a Therapeutic Area Head for Novartis. He received the B.Sc. degree from the University of Surrey and the M.D. and PhD degrees from Cambridge University. Dr. Wei-Ping Min is Professor at the Lawson Health Research Center in Canada. He is inventor of siRNA therapeutics in the area of immunology and cell therapy to inhibit disease modalities. He is also the founder/cofounder of several biotech companies including MedVax Pharma Corp, and ToleroTech Inc. Dr. Min brings detailed scientific and mechanistic expertise to Regen BioPharma. He earned graduate and medical degrees from Nanchang University Medical School and the PhD degree from … Continue reading

Posted in Cell Medicine | Comments Off on Bio-Matrix’ Regen BioPharma Unit Establishes Scientific Advisory Board and Research Relationship With Clinartis in …

Bio-Matrix' Regen BioPharma Unit Establishes Scientific Advisory Board and Research Relationship With Clinartis in …

Posted: Published on June 6th, 2012

SAN DIEGO, CA--(Marketwire -06/06/12)- Bio-Matrix Scientific Group (BMSN) (BMSN) announced today that its Regen BioPharma unit has appointed three internationally renowned regenerative medicine experts to its Scientific Advisory Board (SAB). The new SAB members appointed are David White, M.D., PhD; Wei-Ping Min, M.D., PhD and Vlad Bogin, M.D. Dr. White is a member of the Surgery and Immunology faculty of The Schulic School of Medicine, University of Western Ontario. He is one of the leading experts on using regenerative medicine transplant procedures to treat pancreatic conditions, including diabetes. He is also the Chief Scientific Officer of Sernova Corp and was formerly a Therapeutic Area Head for Novartis. He received the B.Sc. degree from the University of Surrey and the M.D. and PhD degrees from Cambridge University. Dr. Wei-Ping Min is Professor at the Lawson Health Research Center in Canada. He is inventor of siRNA therapeutics in the area of immunology and cell therapy to inhibit disease modalities. He is also the founder/cofounder of several biotech companies including MedVax Pharma Corp, and ToleroTech Inc. Dr. Min brings detailed scientific and mechanistic expertise to Regen BioPharma. He earned graduate and medical degrees from Nanchang University Medical School and the PhD degree from … Continue reading

Posted in Cell Medicine | Comments Off on Bio-Matrix' Regen BioPharma Unit Establishes Scientific Advisory Board and Research Relationship With Clinartis in …

Winner of Nobel Prize for cell work dies

Posted: Published on June 6th, 2012

Andrew Huxley in 1963. CAMBRIDGE, England, June 6 (UPI) -- Andrew Huxley, who shared a 1963 Nobel Prize for his discoveries involving how nerve impulses are transmitted through cells, has died in Britain. His death May 30 was announced by the University of Cambridge, where he served as master of Trinity College from 1984 to 1990, the Los Angeles Times reported Wednesday. Huxley, who died at age 94, shared the 1963 prize in Physiology or Medicine for discovering how nerves generate the electrical impulses that control muscle activities. 2000 Nobel laureate Eric R. Kandel said the discovery "did for the cell biology of neurons what the structure of DNA did for the rest of biology." Working with fellow Nobel laureate Alan Hodgkin, Huxley concluded current was carried by electrically charged atoms called ions, and when the current reached a cell it caused a channel known as a sodium gate to open, allowing sodium ions to flow into the cell. Another gate on the opposite side of the cell would then open, allowing more ions to escape and move the current along to the next cell. Huxley and Hodgkin, who were both knighted in 1974, shared their Nobel with John Eccles … Continue reading

Posted in Cell Medicine | Comments Off on Winner of Nobel Prize for cell work dies

AuxoCell Laboratories Licenses Umbilical Cord Tissue Stem Cell Service to Brazil’s CordVida

Posted: Published on June 6th, 2012

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Leading stem cell therapeutic and regenerative medicine company, AuxoCell Laboratories, Inc., today announced an agreement with CordVida, a Brazilian stem cell cryopreservation company, which will allow CordVida to expand its services. Families who select CordVida to store umbilical cord blood will now have the opportunity to bank stem cells from an additional source cord tissue. With this agreement, AuxoCell broadens its international reach to South America. At AuxoCell, we are pleased by the opportunity to provide this groundbreaking technology to families around the globe, said Rouzbeh R. Taghizadeh, PhD, Chief Scientific Officer of AuxoCell Laboratories, Inc. CordVida is Brazils premier cord blood bank and adheres to the highest quality standards. It is for that reason that we have selected them as our exclusive partner in Brazil. Cord tissue has an abundant source of mesenchymal stem cells (MSCs). Currently, there is a significant amount of research underway focused on mesenchymal stem cells extracted from cord tissue. MSCs are rapidly becoming the leading stem cell in regenerative medicine studies, and MSCs from a variety of sources are in use in over 150 clinical trials. The AuxoCell cord tissue technology represents the gold standard in the industry, as its technology … Continue reading

Posted in Cell Medicine | Comments Off on AuxoCell Laboratories Licenses Umbilical Cord Tissue Stem Cell Service to Brazil’s CordVida

Treatment eases arthritis pain in dogs

Posted: Published on June 6th, 2012

A local veterinary clinic recently added a cuttingedge treatment. Dr. Tina Gemeinhardt, owner of Tsawwassen Animal Hospital, is excited to be offering stem cell therapy to animals suffering from arthritis and joint issues. "I'm excited about trying to bring some relief to dogs that are living in pain," she said. The therapy, which uses stem cells harvested from fat that is surgically removed from the dog, is, in most cases, able to offer relief from the pain and stiffness associated with Gemeinhardt said once it's determined the therapy is the right course of treatment for an animal, body fat is surgically removed and sent to a lab in California where the stem cells are harvested. The harvested stem cells are then sent back to the vet clinic within 48 hours and injected into the joints in question. Gemeinhardt, who added the treatment to the clinic's list of services earlier this year, said it's not quite clear exactly how the stem cells work. "Stem cells seem to inherently know what needs to be done in that area," she said. The treatment is not a cure-all - the arthritis is still there but the symptoms are lessened - and it does not … Continue reading

Posted in Cell Therapy | Comments Off on Treatment eases arthritis pain in dogs

Ocella Drug Side Effects – Video

Posted: Published on June 6th, 2012

05-06-2012 09:41 To read the entire article, click here: To find out more about this and other unsafe products and drugs, click here: See the article here: Ocella Drug Side Effects - Video … Continue reading

Posted in Drug Side Effects | Comments Off on Ocella Drug Side Effects – Video

Drugs most frequently reported for adverse reactions

Posted: Published on June 6th, 2012

by Michael R. Cohen, R.Ph. You may be surprised to learn that in 2011, the Food and Drug Administration received 179,855 reports of serious or fatal adverse drug reactions. This was an increase of 15,386 reports (9.4 percent) from the 2010 total. Reports reached the FDA through two mechanisms. Voluntary reports from health professionals and consumers and reports from manufacturers. There were 21, 002 voluntary reports and 158,853 from manufacturers. Manufacturers must report serious events within 15 days of becoming aware. The 10 drugs with the largest numbers of reports sent directly to the FDA by healthcare practitioners and consumers in 2011 in order of frequency are Pradaxa, Coumadin, Levaquin, Carboplatin, Zestril, Cisplatin, Zocor, Cymbalta, Cipro and Bactrim. Keep in mind that this is not a scientific study of the frequency of adverse drug events in clinical practice. These are the medications that health professionals and consumers told the FDA were causing serious and fatal side effects during 2011. It is interesting to note that just two of these drugs were first introduced in the last decade (Pradaxa and Cymbalta), and only one in the previous year (Pradaxa), suggesting that major drug safety issues are not confined to recently approved … Continue reading

Posted in Drugs | Comments Off on Drugs most frequently reported for adverse reactions

Frost & Sullivan: A 10 Percent Yearly Rise in the Price of Branded Drugs Keeps the Indonesian NSCLC Drugs Market Afloat

Posted: Published on June 6th, 2012

JAKARTA, Indonesia, June 6, 2012 /PRNewswire/ -- Branded NSCLC drugs in Indonesia cost almost three times as much as generic drugs. Their high prices are expected to compensate manufacturers for the decline in sales volumes, as generics is the first line and often, the only form of drug treatment for NSCLC in Indonesia. New analysis from Frost & Sullivan (http://www.pharma.frost.com), The Non-small Cell Lung Cancer Drug Market in Indonesia, finds that the market earned revenues of $16.0 million in 2010 and estimates this to reach $26.0 million in 2015. Branded drugs are sold at price-per-cycle and their volumes drop when the price-per-cycle crosses $850. As the price-per-cycle of generic drugs has not reached the $850 mark yet, their volume is expected to continue rising. The prices of both generic and branded NSCLC drugs could see a spurt along with the increase in transportation and oil costs, since active pharmaceutical ingredients (APIs) are generally imported. However, the market will be sustained by the increasing incidence of NSCLC caused by the high rates of smokers. "The percentage of adult male smokers has increased from 53 percent in 1995 to 66 percent in 2010; and while only 4.2 percent of adult Indonesian women … Continue reading

Posted in Drugs | Comments Off on Frost & Sullivan: A 10 Percent Yearly Rise in the Price of Branded Drugs Keeps the Indonesian NSCLC Drugs Market Afloat

Page 6,806«..1020..6,8056,8066,8076,808..6,8206,830..»